Zydus receives final approval from the USFDA for Acetylcysteine Injection

Zydus receives final approval from the USFDA for Acetylcysteine Injection Ahmedabad, 21 July, 2018 Zydus Cadila has received the final approval from the USFDA to market Acetylcysteine Injection (US RLD - Acetadote Injection ), 6 g/30 mL (200 mg/mL) . It is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. In line with this, the group now has 211 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globa lly. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗